[Incidental diagnosis of medullary thyroid carcinoma (MTC) after performing 123I-metaiodobenzylguanidine (123I-MIBG) gammagraphy].
Gómez Fernández
I
I
Servicio de Medicina Nuclear, Hospital General Universitario Gregorio Marañón, Madrid.
Zugasti Murillo
A
A
Duran Barquero
C
C
Ramos Moreno
E
E
Alonso Farto
J C
JC
Almoguera Arias
M I
MI
Bittini Copano
A
A
Domínguez Montero
P
P
Pérez Vázquez
J M
JM
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging*; D000328:Adult; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging*; D006801:Humans; D033162:Incidental Findings; D008297:Male; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis*; D010673:Pheochromocytoma / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine
Diagnóstico de carcinoma medular de tiroides (CMT) de forma casual tras realización de gammagrafía 123I-metayodobencilguanidina (123I-MIBG).